This hypothesis is further substantiated by the work of Wallukat et al., who detected autoantibodies targeting both adrenergic β2-receptors and muscarinic M2 receptors in all studied patients following COVID-19 (71). This evidence concerns the gene CHRM2 and COVID-19.